Literature DB >> 15826548

[Recommendations from GESIDA/SEFH/PNS to improve adherence to antiviral treatment (2004)].

Hernando Knobel1, Ismael Escobar, Rosa Polo, Luis Ortega, M Teresa Martín-Conde, José Luis Casado, Carlos Codina, Josefina Fernández, M José Galindo, Olatz Ibarra, Monserrat Llinas, Celia Miralles, Melcior Riera, Carmina R Fumaz, Aurea Segador, Ferran Segura, Lourdes Chamorro.   

Abstract

Since the early days of antiretroviral therapy, adherence has emerged as the milestone of success; in fact, it is the most potent predictor of effectiveness. The main factors related to adherence include the complexity of the therapeutic regimen, adverse effects, psychological problems, alcoholism and active addiction to drugs, lack of social and family support and the patient's beliefs and attitudes about the treatment. Adherence monitoring should be part of the HIV patient's regular care, and should be done with feasible, easily applied methods adapted to the different clinical settings. The minimally acceptable measures should include use of a validated questionnaire, together with data from the Pharmacy Department's drug dispensation registry. All patients that begin HAART or undergo a change of treatment should participate in a treatment education program imparted by health professionals with knowledge and experience in the management of patients with HIV infection. The health team (doctors, pharmacists and nursing professionals) should offer maximum availability to solve the doubts and problems that may occur during treatment. When sub-optimal adherence is detected, intervention strategies based on psychological therapy, educational efforts and personal advice should be attempted, in order to adapt the treatment scheme to the patient's habits and provide solutions to the problem of non-compliance. In certain situations, co-morbid conditions will also require attention. Treatment adherence, being a multidimensional problem, needs a multidisciplinary team approach. The choice of therapy, only one aspect of the multidimensional problem of adherence, must be a careful and individualized decision; however, simpler regimens with regard to the number of pills and daily dose are desirable.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15826548     DOI: 10.1157/13073149

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  7 in total

1.  Pilot testing of an HIV medication adherence intervention in a public clinic in the Deep South.

Authors:  Deborah J Konkle-Parker; Judith A Erlen; Patricia M Dubbert; Warran May
Journal:  J Am Acad Nurse Pract       Date:  2012-04-30

2.  Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy.

Authors:  Elena Reina; Ramón San Miguel; Natalia Larrea; Patricia Garcia; Victor Napal
Journal:  Int J Clin Pharm       Date:  2012-09-25

3.  Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.

Authors:  R Palacios; C Hidalgo; M J Ríos; A Rivero; L Muñoz; F Lozano; V Gutiérrez-Ravé; M C Gálvez; A del Arco; J Santos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-08       Impact factor: 3.267

4.  Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations.

Authors:  Margarita García; Ana Clopés; Jordi Bruna; María Martínez; Eduard Fort; Miguel Gil
Journal:  Cancer Manag Res       Date:  2009-10-30       Impact factor: 3.989

5.  HIV drug resistance mutations following poor adherence in HIV-infected patient: a case report.

Authors:  Peter Masikini; Bonaventura C T Mpondo
Journal:  Clin Case Rep       Date:  2015-03-29

6.  A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients.

Authors:  Esther Rodríguez-Gallego; Josep Gómez; Yolanda M Pacheco; Joaquim Peraire; Consuelo Viladés; Raúl Beltrán-Debón; Roger Mallol; Miguel López-Dupla; Sergi Veloso; Verónica Alba; Julià Blanco; Nicolau Cañellas; Anna Rull; Manuel Leal; Xavier Correig; Pere Domingo; Francesc Vidal
Journal:  AIDS       Date:  2018-03-13       Impact factor: 4.177

7.  Glycoprotein Profile Assessed by 1H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study.

Authors:  Ana-Irene Malo; Anna Rull; Josefa Girona; Pere Domingo; Rocío Fuertes-Martín; Núria Amigó; Cèlia Rodríguez-Borjabad; Neus Martínez-Micaelo; Manuel Leal; Joaquim Peraire; Xavier Correig; Francesc Vidal; Lluis Masana
Journal:  J Clin Med       Date:  2020-05-04       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.